『Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial』（Lancet Oncol 2019;20:1655）より まとめ EGFR陽性非小細胞肺…